

### Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

### Listing of Claims

1. – 22. (Cancelled)

23. (Currently Amended) ~~An immunogenic~~A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or adjuvant and an isolated polypeptide that consists of an amino acid sequence at least 90% identical to the full-length amino acid sequence set forth as SEQ ID NO:2, wherein the isolated polypeptide elicits an antibody that specifically binds to a polypeptide that consists of the amino acid sequence set forth as SEQ ID NO:2, and wherein the isolated polypeptide induces an immune response against *Streptococcus pyogenes*.

24. - 37. (Cancelled)

38. (Currently Amended) The ~~immunogenic~~pharmaceutical composition of claim 23 wherein the isolated polypeptide consists of an amino acid sequence at least 95% identical to the full-length amino acid sequence set forth as SEQ ID NO:2.

39. (Currently Amended) The ~~immunogenic~~pharmaceutical composition of claim 23 wherein the isolated polypeptide consists of the amino acid sequence set forth as SEQ ID NO:2.

40. (Currently Amended) ~~An immunogenic~~A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or adjuvant and an isolated polypeptide that comprises an amino acid sequence at least 95% identical to the full-length amino acid sequence set forth as SEQ ID NO:2, wherein the isolated polypeptide elicits an antibody that

specifically binds to a polypeptide that consists of the amino acid sequence set forth as SEQ ID NO:2, and wherein the isolated polypeptide induces an immune response against *Streptococcus pyogenes*.

41. (Currently Amended) The ~~immunogenic-pharmaceutical~~ composition of claim 40 wherein the isolated polypeptide comprises the amino acid sequence set forth as SEQ ID NO:2.

42. (Currently Amended) ~~An immunogenic~~ A pharmaceutical composition comprising (1) a pharmaceutically acceptable carrier, diluent or adjuvant and (2) an isolated polypeptide that comprises an antigenic fragment that consists of at least 15 contiguous amino acids of SEQ ID NO:2, and wherein the antigenic fragment elicits an antibody that specifically binds to a polypeptide that consists of the amino acid sequence set forth as SEQ ID NO:2, and wherein the antigenic fragment induces an immune response against *Streptococcus pyogenes*.

43. – 48. (Cancelled)

49. (New) The pharmaceutical composition of claim 42 wherein the antigenic fragment is coupled to a carrier protein.

50. (New) The pharmaceutical composition of claim 49 wherein the antigenic fragment consists of 15 contiguous amino acids of SEQ ID NO:2.